An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density
lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year
when prescribed with a hypocaloric diet (600 kcal deficit per day) in abdominally obese
patients with atherogenic dyslipidemia (low HDL and/or high TG plasma levels). The secondary
objectives are to evaluate specific metabolic parameters, visceral fat (in selected sites),
safety and tolerability of rimonabant 20 mg.